Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023
An Investigation of a Working Memory Training Program for Neurological Surgery Patients with Various Diagnoses
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
A Phase 3, Open-Label, Randomized, 2 Part Study Comparing Gedatolisib in Combination with Palbociclib & Fulvestrant to SoC Therapies in Patients with HR+ HER2- Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor with Non-Steroidal AI Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
A multiomics profiling study to classify the origin of Cancers of Unknown Primary (CUP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
Blood Coagulation in Cancer Patients
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia or High-risk myelodysplasia
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Phase II study of Polatuzumab vedotin in combination with chemotherapy in subjects with Richter’s Transformation
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated with H. pylori Infection and Gastric Cancer Carcinogenesis
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Liquid Biopsy for Longitudinal Monitoring in Diffuse Midline Glioma (DMG) Patients
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 7, 2023